IM and IV SPL026 Drug Product in Healthy Participants

Open-label interventional study in healthy volunteers (n=14) evaluating SPL026 administered IM and IV. Part A enrolls psychedelic-experienced participants in an IM then IV crossover; Part B enrolls psychedelic‑naive participants for a single IM administration.

Primary assessments include safety and tolerability measures, vital signs and ECG, with screening exclusions to minimise psychiatric and cardiovascular risk; SPL026 is described as DMT by the sponsor.